Answers are grounded in this paper and cite their sources.
Review reveals the regulatory functions of cathelicidin peptide LL-37 in atherosclerosis, thrombosis, and cardiac hypertrophy, highlighting its clinical therapeutic potential.
Heart disease is a common human disease with high morbidity and mortality. Timely and effective prevention and treatment is an urgent clinical problem. The pathogenesis of heart disease is complex and diverse, involving hypertension, diabetes, atherosclerosis, drug toxicity, thrombosis, infection and other aspects. LL-37, an endogenous peptide, is well known for its antimicrobial properties. In recent years, LL-37 has been found to have a variety of biological functions, including its role in the regulation of atherosclerosis, thrombosis, inflammatory responses, and cardiac hypertrophy. Engineered LL-37-related peptides were developed and proved to regulate the development of disease, which revealed its potential clinical application. A comprehensive review and summary of LL-37 is presented to clarify its role in heart disease and to provide a reference and direction for future research.
No takes yet. Share an insight, caveat, or question.
Miao et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: